InVitae (NYSE:NVTA) is set to announce its earnings results after the market closes on Tuesday, August 6th. Analysts expect the company to announce earnings of ($0.48) per share for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.
InVitae (NYSE:NVTA) last posted its quarterly earnings data on Tuesday, May 7th. The medical research company reported ($0.47) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.46) by ($0.01). InVitae had a negative return on equity of 65.76% and a negative net margin of 81.52%. The company had revenue of $40.55 million for the quarter, compared to the consensus estimate of $47.17 million. During the same quarter last year, the business earned ($0.66) EPS. InVitae’s revenue was up 46.5% on a year-over-year basis. On average, analysts expect InVitae to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
InVitae stock traded up $0.70 during mid-day trading on Tuesday, reaching $26.46. 70,938 shares of the company were exchanged, compared to its average volume of 1,743,838. The firm’s fifty day simple moving average is $22.63. InVitae has a 12 month low of $7.73 and a 12 month high of $26.77. The company has a current ratio of 7.73, a quick ratio of 7.73 and a debt-to-equity ratio of 0.37. The company has a market cap of $2.30 billion, a price-to-earnings ratio of -13.65 and a beta of 2.52.
In other news, insider Katherine Stueland sold 3,789 shares of InVitae stock in a transaction on Monday, July 15th. The stock was sold at an average price of $22.49, for a total value of $85,214.61. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Robert L. Nussbaum sold 7,202 shares of InVitae stock in a transaction on Monday, May 20th. The shares were sold at an average price of $18.21, for a total value of $131,148.42. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 93,229 shares of company stock worth $1,701,067. Corporate insiders own 5.70% of the company’s stock.
A number of equities analysts have commented on NVTA shares. Oppenheimer started coverage on Focus Financial Partners in a research note on Monday, April 8th. They set an “outperform” rating and a $48.00 price objective on the stock. Zacks Investment Research lowered Heritage Insurance from a “hold” rating to a “strong sell” rating in a research note on Friday, April 26th. Chardan Capital restated a “buy” rating and set a $30.00 price objective on shares of InVitae in a research note on Tuesday, June 11th. Finally, Benchmark raised their price objective on InVitae from $22.00 to $26.00 and gave the stock a “buy” rating in a research note on Friday, July 12th. Two equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $26.40.
InVitae Company Profile
Invitae Corporation, a genetic information company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. Its tests include genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders, and other hereditary conditions; and screening and testing services in reproductive health, including preimplantation and carrier screening for inherited disorders, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders.
Further Reading: What is quantitative easing?
Receive News & Ratings for InVitae Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae and related companies with MarketBeat.com's FREE daily email newsletter.